Provided by Tiger Trade Technology Pte. Ltd.

Agios Pharmaceuticals

31.91
-0.0100-0.03%
Volume:396.93K
Turnover:12.66M
Market Cap:1.90B
PE:-4.55
High:32.15
Open:31.85
Low:31.53
Close:31.92
52wk High:46.00
52wk Low:22.24
Shares:59.47M
Float Shares:50.09M
Volume Ratio:0.34
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.0075
EPS(LYR):-7.1203
ROE:-34.34%
ROA:-22.24%
PB:1.85
PE(LYR):-4.48

Loading ...

BRIEF-Agios Pharmaceuticals Q1 Product Revenue USD 20.746 Million Vs. IBES Estimate USD 13.6 Million

Reuters
·
Apr 29

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
Apr 29

Agios Pharmaceuticals Q1 Net Income USD -99.111 Million

THOMSON REUTERS
·
Apr 29

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Apr 29

Agios Pharmaceuticals announces annual shareholder meeting notice

Reuters
·
Apr 25

Agios Pharmaceuticals price target lowered to $41 from $44 at BofA

TIPRANKS
·
Apr 21

Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Palvella Therapeutics (PVLA)

TIPRANKS
·
Apr 21

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), GeneDx Holdings (WGS) and Agios Pharma (AGIO)

TIPRANKS
·
Apr 21

U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis

Reuters
·
Apr 21

Agios Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 21

Agios Pharmaceuticals: Mitapivat’s Early-Mover Advantage and Diversified Pipeline Support Buy Rating Despite Emerging Sickle Cell Competition

TIPRANKS
·
Apr 21

H.C. Wainwright cuts Agios target on smaller market post Novo data

TIPRANKS
·
Apr 21

BUZZ-U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO

Reuters
·
Apr 20

Agios Pharmaceuticals falls -23.7%

TIPRANKS
·
Apr 20

Novo's Once-Daily Sickle Cell Pill Hits Milestone. A Smaller Rival Is Sinking 24%. -- Barrons.com

Dow Jones
·
Apr 20

Agios sinks after Novo Nordisk reports sickle cell data

TIPRANKS
·
Apr 20

Agios could come under pressure off Novo Nordisk headline, says Truist

TIPRANKS
·
Apr 20

BUZZ-Agios falls after Novo's sickle cell disease drug shows promise in late-stage study

Reuters
·
Apr 20

Agios Pharma Shares Down 15.5% Premarket After Rival Novo Nordisk Reports Late-Stage Data for Sickle Cell Disease Drug

THOMSON REUTERS
·
Apr 20